and Administration of Medical Devices and related laws and regulations; enterprises to complete all project rectification and by the territory of the provincial drug regulatory authority to review qualified before the resumption of production.
Latest! The cost of selling a batch of pharmaceutical companies has dropped greatly.
Time of Update: 2020-10-30
money from the beginning of the year to the end of the next reporting period because the company does not yet have drugs on the market. sales costs are decreasing It is worth noting that Seber Blue Combs Huahai Pharmaceuticals' third-quarter
The total budget of the regional point method and the payment by disease score have an impact on the geometry of pharmaceutical companies?
Time of Update: 2020-10-29
this paper, the author tries to explore the "regional points method total budget , pay by disease score , big data regulatory use" on the pharmaceutical companies what impact?
18 drug national suspensions involving 14 pharmaceutical companies (attached list)
Time of Update: 2020-10-29
noting that some of the 18 varieties in which the enterprise applied for the removal of the net published the winning bid price - the lowest price is cephalosporine for injection (sodium carbonate), 0.5g x 1 specification price is 1. 27 yuan, the lower
The Central Commission for Discipline Inspection informed: a number of pharmaceutical companies involved in pharmaceutical rebates.
Time of Update: 2020-10-28
the high amount of money involved, corruption interest chain link and so on, resulting in high prices of drugs and medical supplies, medical costs too fast growth, a large number of loss of medical insurance funds and other issues, increasing
The Central Commission for Discipline Inspection informed: a number of pharmaceutical companies involved in pharmaceutical rebates.
Time of Update: 2020-10-28
supplies rebate problem appears the most frequently, showing the high amount of money involved, corruption interest chain link and so on, resulting in high prices of drugs and medical supplies, medical costs too fast growth, a large number of loss
115 pharmaceutical companies reported third-quarter earnings forecasts for a 110-fold increase in the net profit of Sanxiang Bio.
Time of Update: 2020-10-28
/> below to see the performance of the segment. 01, the performance of medical device enterprises is still outstanding, the highest net profit pre-increase of 110 times does not count as the undecloded change in net profit of enterprises, forecast
Several pharmaceutical companies declared bankruptcy.
Time of Update: 2020-10-28
, capital problems and external factors. On this industry phenomenon, Shengshan Asset Executive Director Yu Yichao told Cypress today that this year's Chinese pharmaceutical market is a two-day ice fire, the "28" law is being more and more
In the third quarter, the price of resin products fell, and the subsidiary company withdrew from Soundwater and was awarded 100 million yuan.
Time of Update: 2020-10-27
, the main reason is that the company produced resin and other products prices fell significantly. Subsidiary's exit from Jiangsu Zhongshui Chemical Park received nearly 100 million yuan On July 14, 2020, the company held a meeting of directors
How digital can help pharmaceutical companies ride the waves as change takes place.
Time of Update: 2020-10-27
today, one thing is certain: the trend towards digitalization has not changed. " at the same time, he pointed out that the biggest beneficiaries of the digitalization process is not Internet companies, but the use of the Internet to transform
Latest! The cost of selling a batch of pharmaceutical companies has dropped greatly.
Time of Update: 2020-10-27
-annual report, it has participated in the centralized procurement of drugs in the 4-7 cities organized by the state, the centralized procurement of drugs in the regions of the cross-regional alliance, the second batch of the state and the third batch
Raid check! Well-known medical companies were investigated, many were discontinued!
Time of Update: 2020-10-27
inspection of the main medical device production process of the provincial drug regulatory department, as well as the compliance inspection of the implementation of the relevant production quality management norms.
The ranking of the world's top 100 pharmaceutical companies is open! China dominates 208 Hengrui, stone medicine and other leading charges.
Time of Update: 2020-10-26
capitalization, up 38 places from 68 in 2019. in addition to the overall ranking, Stone Pharmaceuticals Group ranks 2nd in the world in the field of central neuropharmaceuticals by virtue of Erbip, and 16th in the field with GV-971 in Shanghai
"Pharmaceutical Headline King" the world's top 100 pharmaceutical companies ranking open! China dominates 208.
Time of Update: 2020-10-26
(2020/09/28) Reding Pharmaceuticals today opened 9.16% of the main license in how to play a good commercial second half; why Internet medical in and out of the hospital different tunes; layout of Internet hospitals to expand the service radius
"Pharmaceutical headlines" set to promote three years of local leading pharmaceutical companies in what kind of bureau?
Time of Update: 2020-10-26
, 2 new drugs recombinant anti-VEGF humanized monoclonal antibody injection was approved clinical, 1 new drug HEC95468 clinical application was accepted ... So far this year, 9 varieties (17 product regulations) have been approved for market, of which
"Pharmaceutical Headlines" two multinational pharmaceutical companies announced major personnel changes.
Time of Update: 2020-10-26
, in addition to the achievements of business development, pharmaceutical Mingkangde's capital operation is also extremely successful, is China's capital market benchmark enterprises.
Xin Litai: Wen Zhongyi, director of the company, applied for resignation.
Time of Update: 2020-10-26
The board of directors of Shenzhen Xinlitai Pharmaceutical Co., Ltd. announced that it had recently received a written resignation report submitted by Mr. Wen Zhongyi, a director of the company, who had applied to resign as a director
